Abelian quotients of mapping class groups of highly connected manifolds

We compute the abelianisations of the mapping class groups of the manifolds $W_g^{2n} = g(S^n \times S^n)$ for $n \geq 3$ and $g \geq 5$. The answer is a direct sum of two parts. The first part arises from the action of the mapping class group on the middle homology, and takes values in the abelianisation of the automorphism group of the middle homology. The second part arises from bordism classes of mapping cylinders and takes values in the quotient of the stable homotopy groups of spheres by a certain subgroup which in many cases agrees with the image of the stable $J$-homomorphism. We relate its calculation to a purely homotopy theoretic problem.This is the author accepted manuscript. The final version is available from Springer via http://dx.doi.org/10.1007/s00208-015-1300-

The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus Intracoronary

The use of the glycoprotein (GP) IIb/IIIa receptor antagonist Abciximab has over the years become an important part of the anticoagulant regimen in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Abciximab is a potent inhibitor of platelet aggregation and thrombus formation, but other mechanisms, such as suppression of the inflammatory pathways, have also been proposed to contribute to the benefits of Abciximab

Homological stability for moduli spaces of high dimensional manifolds. I

We prove a homological stability theorem for moduli spaces of simply connected manifolds of dimension 2n > 4, with respect to forming connected sum with S$^{n}$ x S$^{n}$ . This is analogous to Harer's stability theorem for the homology of mapping class groups. Combined with previous work of the authors, it gives a calculation of the homology of the moduli spaces of manifolds diffeomorphic to connected sums of S$^{n}$ x S$^{n}$ in a range of degrees.S. Galatius was partially supported by NSF grants DMS-1105058 and DMS-1405001, the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation pro- gramme (grant agreement No 682922), as well as the Danish National Research Foundation through the Centre for Symmetry and Deformation (DNRF92) and ERC-682992. O. Randal-Williams was partially supported by the Herchel Smith Fund and EPSRC grant EP/M027783/1

Tautological rings for high-dimensional manifolds

We study tautological rings for high-dimensional manifolds, that is, for each smooth manifold $M$ the ring $R^*$($M$) of those characteristic classes of smooth fibre bundles with fibre $M$ which is generated by generalised Miller–Morita–Mumford classes. We completely describe these rings modulo nilpotent elements, when $M$ is a connected sum of copies of $S^n$ × $S^n$ for $n$ odd.S.G. was partially supported by NSF grants DMS-1105058 and DMS-1405001, the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement No. 682922), as well as the Danish National Research Foundation through the Centre for Symmetry and Deformation (DNRF92) and ERC-682992. O.R.W. was partially supported by EPSRC grant EP/M027783/1

Integral Grothendieck-Riemann-Roch theorem

We show that, in characteristic zero, the obvious integral version of the Grothendieck-Riemann-Roch formula obtained by clearing the denominators of the Todd and Chern characters is true (without having to divide the Chow groups by their torsion subgroups). The proof introduces an alternative to Grothendieck's strategy: we use resolution of singularities and the weak factorization theorem for birational maps.Comment: 24 page

THE FREQUENCIES OF HAPTOGLOBIN TYPES IN FIVE POPULATIONS *

Haptoglobin types have been determined by starch gel electrophoresis of blood from five populations. The gene frequencies obtained for allele Hp 1 were as follows: American whites, 043; American Negroes, 0.59; African Negroes, 0.72; Apaches, 0.59; and Asiatic Indians, 0.18. In tribes of the Ivory Coast and Liberia, there was a suggestion of a cline which parallels that for haemoglobin S. Evidence is presented that the condition of ahaptoglobinemia is under genetic control but not by a gene allelic to the Hp 1 -Hp 2 series. The importance of the ahaptoglobinemic individuals for genetic studies and the possibility of selection in the maintenance of the genetic polymorphism are discussed. The authors wish to acknowledge the excellent assistance of Alojzia Sandor, who carried out the electrophoretic separations.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/66263/1/j.1469-1809.1958.tb01460.x.pd

Effects of cobalt-chromium everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: Patient level meta-analysis

Objectives: To examine the safety and effectiveness of cobalt-chromium everolimus eluting stents compared with bare metal stents.Design: Individual patient data meta-analysis of randomised controlled trials. Cox proportional regression models stratified by trial, containing random effects, were used to assess the impact of stent type on outcomes. Hazard ratios with 95% confidence interval for outcomes were reported.Data sources and study selection: Medline, Embase, the Cochrane Central Register of Controlled Trials. Randomised controlled trials that compared cobalt-chromium everolimus eluting stents with bare metal stents were selected. The principal investigators whose trials met the inclusion criteria provided data for individual patients.Primary outcomes: The primary outcome was cardiac mortality. Secondary endpoints were myocardial infarction, definite stent thrombosis, definite or probable stent thrombosis, target vessel revascularisation, and all cause death.Results: The search yielded five randomised controlled trials, comprising 4896 participants. Compared with patients receiving bare metal stents, participants receiving cobalt-chromium everolimus eluting stents had a significant reduction of cardiac mortality (hazard ratio 0.67, 95% confidence interval 0.49 to 0.91; P=0.01), myocardial infarction (0.71, 0.55 to 0.92; P=0.01), definite stent thrombosis (0.41, 0.22 to 0.76; P=0.005), definite or probable stent thrombosis (0.48, 0.31 to 0.73; P<0.001), and target vessel revascularisation (0.29, 0.20 to 0.41; P<0.001) at a median follow-up of 720 days. There was no significant difference in all cause death between groups (0.83, 0.65 to 1.06; P=0.14). Findings remained unchanged at multivariable regression after adjustment for the acuity of clinical syndrome (for instance, acute coronary syndrome v stable coro

Cost-effectiveness of percutaneous coronary intervention with cobalt-chromium everolimus eluting stents versus bare metal stents: Results from a patient level meta-analysis of randomized trials

Background: Second-generation drug eluting stents (DES) may reduce costs and improve clinical outcomes compared to first-generation DES with improved cost-effectiveness when compared to bare metal stents (BMS). We aimed to conduct an economic evaluation of a cobalt-chromium everolimus eluting stent (Co-Cr EES) compared with BMS in percutaneous coronary intervention (PCI). Objective: To conduct a cost-effectiveness analysis (CEA) of a cobalt-chromium everolimus eluting stent (Co-Cr EES) versus BMS in PCI. Methods: A Markov state transition model with a 2-year time horizon was applied from a US Medicare setting with patients undergoing PCI with Co-Cr EES or BMS. Baseline characteristics, treatment effects, and safety measures were taken from a patient level meta-analysis of 5 RCTs (n=4,896). The base-case analysis evaluated stent-related outcomes; a secondary analysis considered the broader set of outcomes reported in the meta-analysis. Results: The base-case and secondary analyses reported an additional 0.018 and 0.013 quality-adjusted life years (QALYs) and cost savings of $236 and$288, respectively with Co-Cr EES versus BMS. Results were robust to sensitivity analyses and were most sensitive to the price of clopidogrel. In the probabilistic sensitivity analysis, Co-Cr EES was associated with a greater than 99% chance of being cost savin

Clinical outcomes after treatment of multiple lesions with zotarolimus-eluting versus sirolimus-eluting coronary stents (a SORT OUT III substudy)

<p>Abstract</p> <p>Background</p> <p>Data on clinical outcomes among patients treated with the zotarolimus-eluting Endeavor™ stent versus the sirolimus-eluting Cypher™ stent favor the sirolimus-eluting stent. However, a separate comparison of clinical outcome among patients treated for multiple lesions with these stents is lacking. We performed this comparison within the SORT OUT III trial data set.</p> <p>Methods</p> <p>Among 2332 patients randomized in SORT OUT III, 695 were treated for multiple lesions with zotarolimus-eluting (n = 350) or sirolimus-eluting (n = 345) stents and followed for 18 months. Major adverse cardiac events (MACE); composite of cardiac death, myocardial infarction, or target vessel revascularization (TVR); was the primary endpoint.</p> <p>Results</p> <p>Zotarolimus-eluting compared to sirolimus-eluting stent treatment was associated with increased MACE rate (13.2% vs. 2.6%; hazard ratio 5.29 with 95% confidence interval: 2.59-10.8). All secondary endpoints; all cause death, cardiac death, myocardial infarction, TVR, target lesion revascularization, in-stent restenosis, and definite stent thrombosis; were observed more frequently among zotarolimus-eluting stent treated patients. For all endpoints, hazard ratios were 1.6 to 4.6 times higher than in the overall results of the SORT OUT III trial.</p> <p>Conclusions</p> <p>We observed better clinical outcomes among patients treated for multiple lesions with the sirolimus-eluting stent compared to those treated with the zotarolimus-eluting stent.</p